NATION IN BRIEF : NEW YORK : FDA OKs Drug for Infant Lung Disease
From Times Staff and Wire Reports
The Food and Drug Administration said it has approved a drug that company studies have shown can cut by 50% the death rate in premature infants suffering from a severe lung disease. The disease, called respiratory distress syndrome, is the most common cause of death in infants younger than 30 days, the American Lung Assn. said in New York. The drug, Exosurf, mimics the action of lung surfactant, a liquid that helps keep lungs inflated.
Start your day right
Sign up for Essential California for news, features and recommendations from the L.A. Times and beyond in your inbox six days a week.
You may occasionally receive promotional content from the Los Angeles Times.
